Investors light up Neon with $55M series A

Immuno-oncology newco Neon Therapeutics Inc. raised $55 million in a series A round led by new investor Third Rock Ventures. Other new investors included Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) and Access Industries.

Neon is developing personalized and allogenic therapeutic vaccines and T cell therapies against neoantigens, which result from mutations that occur during tumor growth and are recognized by the immune system as foreign. ...